Skip to content

Study of association of endocannabinoids with neuropathic pain

Study of association of endocannabinoids with neuropathic pain

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066490
Enrollment
Unknown
Registered
2022-12-07
Start date
2022-12-07
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuropathic pain

Interventions

Healthy control group:N/A
Pain patients group:N/A

Sponsors

Zhejiang Provincial People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Pain duration was more than 3 months. 2. Pain intensity (numeric rating scale [NRS] score) was >=4. 3. Age>= 18 years old.

Exclusion criteria

Exclusion criteria: 1. Pain in other parts in the past six months, treated with opioids, antidepressants or anticonvulsants; 2. Taking anticonvulsants or antidepressants for reasons other than neuralgia in the past six months; 3. Presence of severe neurological disease or cognitive impairment; 4. Presence of severe peripheral vascular disease (Fontaine stage >= stage II); 5. Acute infection (blood test to judge); 6. History of alcohol or drug dependence; 7. Difficulties in language communication and comprehension.

Design outcomes

Primary

MeasureTime frame
endocannabinoids;

Countries

China

Contacts

Public ContactJiaqi Hu

Zhejiang Provincial People’s Hospital

juan_hujiaqi@163.com+86 18368192116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026